Your dog was diagnosed with Histiocytic Sarcoma — Localised. Uncommon but breed-associated. Bernese Mountain Dogs have ~25% lifetime prevalence. Arises from dendritic cells. Periarticular location is classic in Bernese Mountain Dogs. Compare 3 treatment options for dogs including Surgery + Adjuvant CCNU (Lomustine), Surgery Alone, CCNU (Lomustine) Monotherapy — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Histiocytic Sarcoma — Localised
Canine Oncology Treatment Guide
Histiocytic Sarcoma — Localised
localised
Round Cell
About This Cancer
Histiocytic sarcoma arises from dendritic cells, which are specialised immune cells that normally help the body recognise and respond to threats. In the localised form, the cancer develops as a single mass, most commonly in or around joints (periarticular), the spleen, lungs, or under the skin. The Bernese Mountain Dog is dramatically predisposed, with roughly one in four developing this disease during their lifetime — a hereditary susceptibility that remains an active focus of breed health research. Flat-Coated Retrievers, Rottweilers, and Golden Retrievers are also at increased risk. While the localised form has a better outlook than the disseminated form, it remains an aggressive cancer that frequently spreads if not treated promptly, and surgery combined with chemotherapy offers the best chance of meaningful disease control.
Localised vs Disseminated Classification
Histiocytic sarcoma is classified as localised (single site) or disseminated (multiple organs). Localised disease has significantly better prognosis.
Prognostic Factors(2)
Minimum Workup(5 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.